SHARE IN FOCUS: Morphosys on the decline by numbers – multi-year low
Scientists at work in a medical laboratory (symbolic image). © SolStock / E + / Getty Images
FRANKFURT (dpa-AFX) – The shares of the biotechnology company Morphosys (MorphoSys share)
Analyst Vineet Agrawal from Citigroup (Citigroup share) judged in a study on Thursday that the share continues to lack a timely price driver. For some time now, paper has been one of the big losers on the stock market. Since the multi-year high of 146.30 at the beginning of 2020, it has fallen by around 75 percent – no other German standard value has lost more in the period. The company is only worth around 1.2 billion euros on the stock exchange.
Because of the drop in the share price, the company also got out of the MDax in September
|Short-term position in MorphoSys|
|with moderate leverage|
HSBC Trinkaus & Burkhardt AG
Subscribe to more news about American Lithium shares for free
ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that is recognizably posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.
Other users were also interested in this article: